Bausch Health Companies Inc. Accrued Income Taxes, Current
Bausch Health Companies Inc. (BHC) had Accrued Income Taxes, Current of $49.00 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2026-07-30
- 2026-06-30: Accrued Income Taxes, Current $49.00M.
- 2026-03-31: Accrued Income Taxes, Current $48.00M.
- 2025-12-31: Accrued Income Taxes, Current $38.00M.
- 2025-09-30: Accrued Income Taxes, Current $124.00M.
| Period end | Accrued Income Taxes, Current | Accrued Income Taxes, Current as first filed |
|---|---|---|
| 2026-06-30 | $49.00M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $48.00M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $38.00M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $124.00M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $104.00M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $76.00M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $63.00M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $102.00M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $78.00M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $76.00M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $47.00M 10-K · filed 2025-02-20 | |
| 2023-09-30 | $70.00M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $52.00M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $46.00M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $30.00M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $66.00M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $59.00M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $80.00M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $98.00M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $111.00M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $110.00M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $132.00M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $158.00M 8-K · filed 2022-05-11 | |
| 2020-09-30 | $149.00M 10-Q · filed 2020-11-03 | |
| 2020-06-30 | $170.00M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $184.00M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $196.00M 8-K · filed 2021-05-04 | |
| 2019-09-30 | $150.00M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $150.00M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $167.00M 10-Q · filed 2019-05-06 | |
| 2018-12-31 | $167.00M 10-K · filed 2020-02-19 | |
| 2018-09-30 | $156.00M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $186.00M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $190.00M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $202.00M 10-K · filed 2019-02-20 | |
| 2017-09-30 | $163.00M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $163.00M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $213.00M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $213.00M 8-K · filed 2018-08-10 | |
| 2015-12-31 | $221.00M 10-K · filed 2017-03-01 | $221.30M 10-K · filed 2016-04-29 |
| 2014-12-31 | $122.90M 10-K · filed 2016-04-29 | |
| 2013-12-31 | $39.10M 10-K · filed 2015-02-25 | $39.10M 10-K · filed 2014-02-28 |
| 2012-12-31 | $19.91M 10-K · filed 2014-02-28 | |
| 2012-09-30 | $10.21M 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $15.54M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $8.24M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $10.34M 10-K · filed 2013-02-28 | |
| 2011-09-30 | $41.64M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $67.55M 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $8.78M 10-Q · filed 2011-05-10 | |
| 2010-12-31 | $9.15M 10-K · filed 2012-02-29 | |
| 2010-09-30 | $15.26M 10-Q · filed 2010-11-05 | |
| 2010-06-30 | $11.32M 10-Q · filed 2010-08-06 | |
| 2009-12-31 | $6.85M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |